PS522501

PS522501 is a small molecule protein-protein interaction (PPI) modulator developed by Prosetta Biosciences, primarily investigated for the treatment of amyotrophic lateral sclerosis (ALS). The compound was identified using Prosetta's proprietary Prosetta Assembly Discovery (PAD) platform, which focuses on identifying drugs that regulate the assembly of multiprotein complexes rather than targeting individual proteins. PS522501 specifically targets the TAR DNA-binding protein 43 (TDP-43), a protein whose misfolding and cytoplasmic aggregation are hallmark pathological features of ALS and frontotemporal lobar degeneration. By modulating the assembly pathway of TDP-43, PS522501 aims to prevent the formation of toxic aggregates and maintain the protein's normal physiological function, thereby offering a potential neuroprotective therapeutic strategy to slow disease progression.